These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 26995013)
1. In vitro and in vivo evaluations of the P-glycoprotein-mediated efflux of dibenzoylhydrazines. Miyata K; Nakagawa Y; Kimura Y; Ueda K; Akamatsu M Toxicol Appl Pharmacol; 2016 May; 298():40-7. PubMed ID: 26995013 [TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships of dibenzoylhydrazines for the inhibition of P-glycoprotein-mediated quinidine transport. Miyata K; Nakagawa Y; Kimura Y; Ueda K; Akamatsu M Bioorg Med Chem; 2016 Jul; 24(14):3184-91. PubMed ID: 27262425 [TBL] [Abstract][Full Text] [Related]
3. Use of cassette dosing approach to examine the effects of P-glycoprotein on the brain and cerebrospinal fluid concentrations in wild-type and P-glycoprotein knockout rats. Liu X; Cheong J; Ding X; Deshmukh G Drug Metab Dispos; 2014 Apr; 42(4):482-91. PubMed ID: 24398459 [TBL] [Abstract][Full Text] [Related]
4. Modulating effect of polyethylene glycol on the intestinal transport and absorption of prednisolone, methylprednisolone and quinidine in rats by in-vitro and in-situ absorption studies. Shen Q; Li W; Lin Y; Katsumi H; Okada N; Sakane T; Fujita T; Yamamoto A J Pharm Pharmacol; 2008 Dec; 60(12):1633-41. PubMed ID: 19000368 [TBL] [Abstract][Full Text] [Related]
5. A simplified protocol employing elacridar in rodents: a screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier. Kallem R; Kulkarni CP; Patel D; Thakur M; Sinz M; Singh SP; Mahammad SS; Mandlekar S Drug Metab Lett; 2012 Jun; 6(2):134-44. PubMed ID: 23061481 [TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein inhibition by the agricultural pesticide propiconazole and its hydroxylated metabolites: Implications for pesticide-drug interactions. Mazur CS; Marchitti SA; Zastre J Toxicol Lett; 2015 Jan; 232(1):37-45. PubMed ID: 25268938 [TBL] [Abstract][Full Text] [Related]
7. pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs: kinetic analysis of quinidine efflux in situ. Varma MV; Panchagnula R J Pharm Sci; 2005 Dec; 94(12):2632-43. PubMed ID: 16258992 [TBL] [Abstract][Full Text] [Related]
8. Convallatoxin: a new P-glycoprotein substrate. Gozalpour E; Greupink R; Bilos A; Verweij V; van den Heuvel JJ; Masereeuw R; Russel FG; Koenderink JB Eur J Pharmacol; 2014 Dec; 744():18-27. PubMed ID: 25264938 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic interaction of green tea beverage containing cyclodextrins and high concentration catechins with P-glycoprotein substrates in LLC-GA5-COL150 cells in vitro and in the small intestine of rats in vivo. Oda K; Murakami T J Pharm Pharmacol; 2017 Dec; 69(12):1736-1744. PubMed ID: 28980319 [TBL] [Abstract][Full Text] [Related]
10. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. El Ela AA; Härtter S; Schmitt U; Hiemke C; Spahn-Langguth H; Langguth P J Pharm Pharmacol; 2004 Aug; 56(8):967-75. PubMed ID: 15285840 [TBL] [Abstract][Full Text] [Related]
11. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier. Hsiao P; Bui T; Ho RJ; Unadkat JD Drug Metab Dispos; 2008 Mar; 36(3):481-4. PubMed ID: 18057117 [TBL] [Abstract][Full Text] [Related]
12. In vitro to in vivo evidence of the inhibitor characteristics of Schisandra lignans toward P-glycoprotein. Liang Y; Zhou Y; Zhang J; Liu Y; Guan T; Wang Y; Xing L; Rao T; Zhou L; Hao K; Xie L; Wang GJ Phytomedicine; 2013 Aug; 20(11):1030-8. PubMed ID: 23731657 [TBL] [Abstract][Full Text] [Related]
13. Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin. Zong J; Pollack GM J Pharmacol Exp Ther; 2003 Aug; 306(2):556-62. PubMed ID: 12721332 [TBL] [Abstract][Full Text] [Related]
16. Marked impact of P-glycoprotein on the absorption of TAK-427 in rats. Takeuchi T; Nonaka M; Yoshitomi S; Higuchi T; Ebihara T; Maeshiba Y; Kawase M; Asahi S Biopharm Drug Dispos; 2008 Sep; 29(6):311-23. PubMed ID: 18651556 [TBL] [Abstract][Full Text] [Related]
17. Membrane Assays to Characterize Interaction of Drugs with ABCB1. Fekete Z; Rajnai Z; Nagy T; Jakab KT; Kurunczi A; Gémes K; Herédi-Szabó K; Fülöp F; Tóth GK; Czerwinski M; Loewen G; Krajcsi P J Membr Biol; 2015 Dec; 248(6):967-77. PubMed ID: 25926125 [TBL] [Abstract][Full Text] [Related]
18. Substrate- and species-dependent inhibition of P-glycoprotein-mediated transport: implications for predicting in vivo drug interactions. Zolnerciks JK; Booth-Genthe CL; Gupta A; Harris J; Unadkat JD J Pharm Sci; 2011 Aug; 100(8):3055-3061. PubMed ID: 21484807 [TBL] [Abstract][Full Text] [Related]
19. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats. Sugimoto H; Hirabayashi H; Kimura Y; Furuta A; Amano N; Moriwaki T Drug Metab Dispos; 2011 Jan; 39(1):8-14. PubMed ID: 20962062 [TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Kim WY; Benet LZ Pharm Res; 2004 Jul; 21(7):1284-93. PubMed ID: 15290871 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]